Skip to content
TrialScanner

NCT02296190

Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm

Phase 2CompletedMISTLeadMEDPCollaborator

Registry record

Lead sponsor
Milestone Pharmaceuticals Inc.
Conditions
Paroxysmal Supraventricular Tachycardia (PSVT)
Primary completion
Dec 2016Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02296190 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02296190: Efficacy and Safety of... | TrialScanner